Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind Placebo Controlled Study of Atomoxetine Hydrochloride for the Treatment of ADHD in Children and Adolescents With ADHD and Comorbid Dyslexia

NCT00607919 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00607919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00607919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind Placebo Controlled Study of Atomoxetine Hydrochloride for the Treatment of ADHD in Children and Adolescents With ADHD and Comorbid Dyslexia
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2008
Completion date
February 28, 2011
Enrollment
209 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit hyperactivity disorder, dyslexia